{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:36:14Z","timestamp":1775914574311,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Medical Award Foundation","award":["YXJL-2022-0080-0168"],"award-info":[{"award-number":["YXJL-2022-0080-0168"]}]},{"name":"Haiyan Foundation of Harbin Medical University Cancer Hospital","award":["JJZD2014-06"],"award-info":[{"award-number":["JJZD2014-06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Synaptogyrin-2 (SYNGR2), as a member of synaptogyrin gene family, is overexpressed in several types of cancer. However, the role of SYNGR2 in pan-cancer is largely unexplored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From the TCGA and GEO databases, we obtained bulk transcriptomes, and clinical information. We examined the expression patterns, prognostic values, and diagnostic value of SYNGR2 in pan-cancer, and investigated the relationship of SYNGR2 expression with tumor mutation burden (TMB), microsatellite instability (MSI), immune infiltration, and immune checkpoint (ICP) genes. The gene set enrichment analysis (GSEA) software was used to perform pathway analysis. Besides, we built a nomogram of liver hepatocellular carcinoma patients (LIHC) and validated its prediction accuracy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SYNGR2 was highly expressed in most cancers. The high expression of SYNGR2 significantly reduced the overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in multiple types of cancer. Also, receiver operating characteristic (ROC) curve analysis demonstrated that SYNGR2 showed high accuracy in distinguishing cancerous tissues from normal ones. Moreover, SYNGR2 expression was correlated with TMB, MSI, immune scores, and immune cell infiltrations. We also analyzed the association of SYNGR2 with immunotherapy response in LIHC. Finally, a nomogram including SYNGR2 and pathologic T, N, M stage was built and exhibited good predictive power for the OS, DSS, and PFI of LIHC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Overall, SYNGR2 is a critical oncogene in various tumors. SYNGR2 participates in the carcinogenic progression, and may contribute to the immune infiltration in tumor microenvironment. Our study suggests that SYNGR2 can serve as a predictor related to prognosis in pan-cancer, especially LIHC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-023-05323-y","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:02:41Z","timestamp":1683788561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Chunxun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaowei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"5323_CR1","doi-asserted-by":"crossref","unstructured":"Collaborators GBDCRF. The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-91","DOI":"10.1016\/S0140-6736(22)01438-6"},{"key":"5323_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5323_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20(4):209\u201315.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"5323_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s004390050795","volume":"103","author":"D Kedra","year":"1998","unstructured":"Kedra D, Pan HQ, Seroussi E, et al. Characterization of the human synaptogyrin gene family. Hum Genet. 1998;103(2):131\u201341.","journal-title":"Hum Genet"},{"issue":"14","key":"5323_CR5","first-page":"2423","volume":"128","author":"D Kioumourtzoglou","year":"2015","unstructured":"Kioumourtzoglou D, Pryor PR, Gould GW, et al. Alternative routes to the cell surface underpin insulin-regulated membrane trafficking of GLUT4. J Cell Sci. 2015;128(14):2423\u20139.","journal-title":"J Cell Sci"},{"key":"5323_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1471-2407-10-196","volume":"10","author":"MH Tan","year":"2010","unstructured":"Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196.","journal-title":"BMC Cancer"},{"issue":"8","key":"5323_CR7","doi-asserted-by":"publisher","first-page":"e3441","DOI":"10.1002\/jgm.3441","volume":"24","author":"B Li","year":"2022","unstructured":"Li B, Ren MY, Chen YZ, et al. SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma. J Gene Med. 2022;24(8):e3441.","journal-title":"J Gene Med"},{"issue":"7793","key":"5323_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/d41586-020-00213-2","volume":"578","author":"M Cieslik","year":"2020","unstructured":"Cieslik M, Chinnaiyan A. Global genomics project unravels cancer\u2019s complexity at unprecedented scale. Nature. 2020;578(7793):39\u201340.","journal-title":"Nature"},{"issue":"W1","key":"5323_CR9","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5323_CR10","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-019-13528-0","volume":"10","author":"F Chen","year":"2019","unstructured":"Chen F, Chandrashekar D, Varambally S, et al. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10(1):5679.","journal-title":"Nat Commun"},{"issue":"8","key":"5323_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"D Chandrashekar","year":"2017","unstructured":"Chandrashekar D, Bashel B, Balasubramanya S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649\u201358.","journal-title":"Neoplasia"},{"key":"5323_CR12","doi-asserted-by":"publisher","first-page":"732822","DOI":"10.3389\/fgene.2021.732822","volume":"12","author":"K Zhao","year":"2021","unstructured":"Zhao K, Ma Z, Zhang W. SPP1 comprehensive analysis to identify as a prognostic biomarker in cervical cancer. Front Genet. 2021;12:732822.","journal-title":"Front Genet"},{"issue":"43","key":"5323_CR13","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha V, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5323_CR14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"5323_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"5323_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"1","key":"5323_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"4","key":"5323_CR18","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.jtcvs.2017.12.107","volume":"155","author":"SY Park","year":"2018","unstructured":"Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"5323_CR19","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1158\/1078-0432.CCR-19-3663","volume":"26","author":"C Aggarwal","year":"2020","unstructured":"Aggarwal C, Thompson JC, Chien AL, et al. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2020;26(10):2354\u201361.","journal-title":"Clin Cancer Res"},{"key":"5323_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti M, Le D. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45\u201362.","journal-title":"Pharmacol Ther"},{"key":"5323_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","volume":"14","author":"J Trowsdale","year":"2013","unstructured":"Trowsdale J, Knight J. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301\u201323.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"5323_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N Mcgranahan","year":"2017","unstructured":"Mcgranahan N, Rosenthal R, Hiley C, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259\u201371.","journal-title":"Cell"},{"issue":"1","key":"5323_CR23","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"16","key":"5323_CR24","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.3748\/wjg.v21.i16.4864","volume":"21","author":"KQ Han","year":"2015","unstructured":"Han KQ, He XQ, Ma MY, et al. Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma. World J Gastroenterol. 2015;21(16):4864\u201374.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"5323_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha M, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5323_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm A, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885-900.e10.","journal-title":"Cancer Cell"},{"issue":"5","key":"5323_CR27","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1074\/jbc.273.5.2851","volume":"273","author":"R Janz","year":"1998","unstructured":"Janz R, S\u00fcdhof T. Cellugyrin, a novel ubiquitous form of synaptogyrin that is phosphorylated by pp60c-src. J Biol Chem. 1998;273(5):2851\u20137.","journal-title":"J Biol Chem"},{"issue":"18","key":"5323_CR28","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"2","key":"5323_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1152\/physrev.00008.2020","volume":"101","author":"KF Goliwas","year":"2021","unstructured":"Goliwas KF, Deshane JS, Elmets CA, et al. Moving immune therapy forward targeting TME. Physiol Rev. 2021;101(2):417\u201325.","journal-title":"Physiol Rev"},{"issue":"9","key":"5323_CR30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","volume":"22","author":"CY Ock","year":"2016","unstructured":"Ock CY, Keam B, Kim S, et al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res. 2016;22(9):2261\u201370.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5323_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/cam4.1889","volume":"8","author":"S Shimizu","year":"2019","unstructured":"Shimizu S, Hiratsuka H, Koike K, et al. Tumor-infiltrating CD8 T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8(1):80\u201393.","journal-title":"Cancer Med"},{"issue":"7","key":"5323_CR32","doi-asserted-by":"publisher","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","volume":"8","author":"Q Fu","year":"2019","unstructured":"Fu Q, Chen N, Ge C, et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019;8(7):1593806.","journal-title":"Oncoimmunology"},{"issue":"1","key":"5323_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1586\/1744666X.2014.865519","volume":"10","author":"A Bhatia","year":"2014","unstructured":"Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol. 2014;10(1):41\u201362.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"5323_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan F, Somasundaram A, Bruno TC, et al. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8(11):944\u201361.","journal-title":"Trends Cancer"},{"issue":"11","key":"5323_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2696","volume":"9","author":"HZ Chen","year":"2009","unstructured":"Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5323_CR36","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1245\/s10434-012-2519-8","volume":"20","author":"YL Chen","year":"2013","unstructured":"Chen YL, Uen YH, Li CF, et al. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol. 2013;20(12):4041\u201354.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"5323_CR37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/cells9041038","volume":"9","author":"M Beaulieu","year":"2020","unstructured":"Beaulieu M, Castillo F, Soucek L. Structural and biophysical insights into the function of the intrinsically disordered myc oncoprotein. Cells. 2020;9(4):1038.","journal-title":"Cells"},{"key":"5323_CR38","doi-asserted-by":"publisher","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"M Duffy","year":"2021","unstructured":"Duffy M, O\u2019grady S, Tang M, et al. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.","journal-title":"Cancer Treat Rev"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05323-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-023-05323-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-023-05323-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:02:56Z","timestamp":1683788576000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-023-05323-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5323"],"URL":"https:\/\/doi.org\/10.1186\/s12859-023-05323-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}